Neoadjuvant treatment with imatinib could help make huge and low-lying rectal gastrointestinal stromal tumor (GIST) operable and lead to better surgical outcomes, according to a new study published in PLoS One. Rectal GIST is very rare, comprising 5% of all GISTs, which are rare themselves. However, rectal GIST has the worst prognosis and a recurrence…
Laparoscopic surgery is a minimally invasive and potentially useful way to remove gastrointestinal stromal tumors (GISTs) arising outside of the gastrointestinal tract, according to a case study published in the International Journal of Surgery Case Reports. “Ruptured extragastrointestinal stromal [tumors] (EGIST) are rare; therefore, there are no standard guidelines for its treatment. Herein, we report…
Endoscopic ultrasonography assisted by artificial intelligence is highly accurate in diagnosing gastrointestinal stromal tumors (GISTs), according to a meta-analysis. The results showed that the pooled sensitivity of artificial intelligence-assisted endoscopic ultrasonography in differentiating GIST from other submucosal tumors was 0.92. Its specificity was 0.82, and the positive and negative likelihood ratios were 4.55 and 0.12,…
A new method using Photoshop and endoscopic ultrasound combined can help to better differentiate between gastrointestinal stromal tumors (GIST) and leiomyomas, according to new research findings. These data showed that the mean gray value of the tumor was significantly higher in GIST compared to leiomyomas. The ratios of the mean gray value of tumor to…
Novel insight into the epidemiological, clinical, and therapeutic data of gastrointestinal stromal tumors (GISTs) of the duodenum may lead to unified recommendations on their management and that of other primary duodenal malignant tumors (PDMT), according to a study recently published in the Journal of Gastrointestinal Oncology. “In this retrospective study, we sought to analyze and evaluate…
The use of radiomics features can effectively predict recurrence-free survival (RFS) and benefits of postsurgical adjuvant therapy in patients with an intermediate- or high-risk gastrointestinal stromal tumor (GIST), according to the results of a recently published study in La Radiologia Medica, the official journal of the Italian Society of Medical Radiology. Recognizing that GISTs are…
Significant muscle loss during neoadjuvant therapy with imatinib may be associated with postsurgical complications and a worse prognosis in patients with gastrointestinal stromal tumor (GIST). According to a study published in BMC Gastroenterology, GIST patients with significant muscle loss had a significantly higher rate of postoperative complications than those who did not have significant muscle…
Positron emission tomography(PT)/computed tomography (CT) scans utilizing radioactive fluorine [18F]-labeled fibroblast activation protein inhibitor-42 ([18F]FAPI-42) detected more recurrent or metastatic gastrointestinal stromal tumors (GISTs) than PET/CT imaging using labeled fluorodeoxyglucose ([18F]FDG) according to a new study published in the European Journal of Nuclear Medicine and Molecular Imaging. During the study, a total of 106 lesions…
The Alliance for Regenerative Medicine aims to help in the development of safe and effective regenerative therapies that can benefit rare disease patients.
In patients with a gastrointestinal stromal tumor (GIST), the risk for malignancy can be evaluated with the use of noninvasive radiomics, according to the results of an analysis published in Frontiers in Oncology. A retrospective, multicenter study was conducted among patients with a confirmed histopathologic GIST from 5 medical centers in China. Data from computed…
